Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

BACKGROUND: Because of limited efficacy of antipsychotics against negative symptoms in schizophrenia new drugs with wider spectrums of clinical efficacy are very desirable. The newer 3rd generation antipsychotic cariprazine presents the unique mode of action acting as partial agonist predominantly f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanov, Stanislav V., Smulevich, Anatoly B., Voronova, Evgeniya I., Yakhin, Kausar K., Beybalaeva, Tangyul Z., Katok, Alena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818881/
https://www.ncbi.nlm.nih.gov/pubmed/35140638
http://dx.doi.org/10.3389/fpsyt.2021.770592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818881/
https://www.ncbi.nlm.nih.gov/pubmed/35140638
http://dx.doi.org/10.3389/fpsyt.2021.770592

Ejemplares similares